Johnson & Johnson Revenue 2011-2025 | JNJ
Johnson & Johnson annual/quarterly revenue history and growth rate from 2011 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Johnson & Johnson revenue for the quarter ending September 30, 2025 was $23.993B, a 6.77% increase year-over-year.
- Johnson & Johnson revenue for the twelve months ending September 30, 2025 was $92.149B, a 5.08% increase year-over-year.
- Johnson & Johnson annual revenue for 2024 was $88.821B, a 4.3% increase from 2023.
- Johnson & Johnson annual revenue for 2023 was $85.159B, a 6.46% increase from 2022.
- Johnson & Johnson annual revenue for 2022 was $79.99B, a 1.59% increase from 2021.
|
Johnson & Johnson Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $88,821 |
| 2023 | $85,159 |
| 2022 | $79,990 |
| 2021 | $78,740 |
| 2020 | $82,584 |
| 2019 | $82,059 |
| 2018 | $81,581 |
| 2017 | $76,450 |
| 2016 | $71,890 |
| 2015 | $70,074 |
| 2014 | $74,331 |
| 2013 | $71,312 |
| 2012 | $67,224 |
| 2011 | $65,030 |
| 2010 | $61,587 |
|
Johnson & Johnson Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2025-09-30 | $23,993 |
| 2025-06-30 | $23,743 |
| 2025-03-31 | $21,893 |
| 2024-12-31 | $22,520 |
| 2024-09-30 | $22,471 |
| 2024-06-30 | $22,447 |
| 2024-03-31 | $21,383 |
| 2023-12-31 | $21,395 |
| 2023-09-30 | $21,351 |
| 2023-06-30 | $21,519 |
| 2023-03-31 | $20,894 |
| 2022-12-31 | $12,548 |
| 2022-09-30 | $19,996 |
| 2022-06-30 | $24,020 |
| 2022-03-31 | $23,426 |
| 2021-12-31 | $9,769 |
| 2021-09-30 | $23,338 |
| 2021-06-30 | $23,312 |
| 2021-03-31 | $22,321 |
| 2020-12-31 | $22,475 |
| 2020-09-30 | $21,082 |
| 2020-06-30 | $18,336 |
| 2020-03-31 | $20,691 |
| 2019-12-31 | $20,747 |
| 2019-09-30 | $20,729 |
| 2019-06-30 | $20,562 |
| 2019-03-31 | $20,021 |
| 2018-12-31 | $20,394 |
| 2018-09-30 | $20,348 |
| 2018-06-30 | $20,830 |
| 2018-03-31 | $20,009 |
| 2017-12-31 | $20,195 |
| 2017-09-30 | $19,650 |
| 2017-06-30 | $18,839 |
| 2017-03-31 | $17,766 |
| 2016-12-31 | $18,106 |
| 2016-09-30 | $17,820 |
| 2016-06-30 | $18,482 |
| 2016-03-31 | $17,482 |
| 2015-12-31 | $17,811 |
| 2015-09-30 | $17,102 |
| 2015-06-30 | $17,787 |
| 2015-03-31 | $17,374 |
| 2014-12-31 | $18,254 |
| 2014-09-30 | $18,467 |
| 2014-06-30 | $19,495 |
| 2014-03-31 | $18,115 |
| 2013-12-31 | $18,355 |
| 2013-09-30 | $17,575 |
| 2013-06-30 | $17,877 |
| 2013-03-31 | $17,505 |
| 2012-12-31 | $17,558 |
| 2012-09-30 | $17,052 |
| 2012-06-30 | $16,475 |
| 2012-03-31 | $16,139 |
| 2011-12-31 | $16,255 |
| 2011-09-30 | $16,005 |
| 2011-06-30 | $16,597 |
| 2011-03-31 | $16,173 |
| 2010-12-31 | $15,644 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $468.343B | $88.821B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $962.193B | 46.28 |
| AbbVie (ABBV) | United States | $412.207B | 24.68 |
| Roche Holding AG (RHHBY) | Switzerland | $289.080B | 0.00 |
| Novartis AG (NVS) | Switzerland | $279.452B | 14.81 |
| Merck (MRK) | United States | $226.981B | 10.57 |
| Novo Nordisk (NVO) | Denmark | $224.411B | 13.16 |
| Pfizer (PFE) | United States | $147.089B | 8.08 |
| Sanofi (SNY) | France | $127.490B | 12.24 |
| Bayer (BAYRY) | Germany | $32.892B | 5.77 |
| Innoviva (INVA) | United States | $1.404B | 8.34 |